Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26

Mumbai (Maharashtra) [India], November 11: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and animal healthcare products, has reported its Unaudited financials for Q2 FY26 & H1 FY26. Key Financial Highlights Q2 FY26 Standalone Financial Highlights • Total Income [...]

PNN
PNN Syndicated | Wire Content | Press Release • 27 Sep, 2026Chief Editor
November 11, 2025 • 6:54 PM
B
Business
NEWS CARD
Logo
Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26
“Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26”
Favicon
Read more onen.marudharabharti.com
11 Nov 2025
https://en.marudharabharti.com/fredun-pharmaceuticals-reports-61-percent-yoy-growth-in-ebitda-to-inr-3933-cr-in-h1-fy26
Copied
Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26
Fredun Pharmaceuticals Reports 61 percent YoY Growth in EBITDA to INR 39.33 Cr in H1 FY26

Mumbai (Maharashtra) [India], November 11: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), is one of the Leading Pharmaceuticals Formulation manufacturing companies in India. Diversified into Generics, Cosmeceuticals, Nutraceuticals, Mobility and animal healthcare products, has reported its Unaudited financials for Q2 FY26 & H1 FY26.

Key Financial Highlights

Q2 FY26 Standalone Financial Highlights

rss_feed Disclaimer
Story published through syndicated feed
favorite Follow us for the latest updates:
PNN

PNN Syndicated | Wire Content | Press Release • 27 Sep, 2026Chief Editor

homeHomeamp_storiesWeb Storieslocal_fire_departmentTrendingplay_circleVideosmark_email_unreadNewsletter